V. Kunene , M. Ding , M. Yap , E.A. Griffiths , P. Taniere , D. Fackrell , S. Butler , G. Contino
{"title":"Prognostic markers in oesophageal and gastric cancer review. Are they ready for clinical practice?","authors":"V. Kunene , M. Ding , M. Yap , E.A. Griffiths , P. Taniere , D. Fackrell , S. Butler , G. Contino","doi":"10.1016/j.esmogo.2024.100091","DOIUrl":null,"url":null,"abstract":"<div><div>Oesophageal and gastric cancer outcomes remain poor despite the introduction of new treatments in the past decade. Most patients subjected to chemotherapy or surgery do not, in the long term, benefit from treatment but suffer side-effects. Although next-generation sequencing has accelerated the identification of various genomic aberrations, most have yet to be applied to routine clinical practice. Here, we review published data from systemic reviews and meta-analyses from the past 8 years reporting prognostic markers and why these have not gained traction in clinical practice and how we can improve on this.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"6 ","pages":"Article 100091"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Gastrointestinal Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949819824000529","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Oesophageal and gastric cancer outcomes remain poor despite the introduction of new treatments in the past decade. Most patients subjected to chemotherapy or surgery do not, in the long term, benefit from treatment but suffer side-effects. Although next-generation sequencing has accelerated the identification of various genomic aberrations, most have yet to be applied to routine clinical practice. Here, we review published data from systemic reviews and meta-analyses from the past 8 years reporting prognostic markers and why these have not gained traction in clinical practice and how we can improve on this.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
